Local research. Human connections. WCR Miami Lakes (786) 483-7856
Back to study searchNCT07754838
Not yet recruitingNCT07754838ClinicalTrials.gov record

Acoustic Stimulation to Study and Modulate Sleepwalking and Related Arousal Disorders

NREM Parasomnias · Sleepwalking · Sleep Terrors · Confusional Arousals

THE QUICK READ

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type
Interventional
Phase
Not applicable
Age range
6 years - 60 years
Sex eligible
All sexes
Healthy volunteers
Accepted
Participants
50 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

Disorders of Arousal (DoA)-such as sleepwalking, sleep terrors, and confusional arousals-are common sleep problems that happen during deep, non-dreaming sleep. Researchers do not fully understand what triggers these episodes or how to influence them.

This study tests whether playing soft sounds during sleep can help researchers learn more about, and possibly induce or modulate, these episodes under safe, supervised conditions. Participants with DoA will spend two nights in the sleep laboratory, with painless sensors placed on the scalp and body (similar to a regular sleep study). On one night, no sound is played. On the other night, soft sounds are played during deep sleep. The order of the two nights is decided randomly for each participant.

A small group of healthy volunteers without DoA will also take part, undergoing a single night with sound stimulation, to help researchers understand whether the sounds affect everyone the same way or specifically trigger episodes in people with DoA.

A subgroup of participants with DoA will also take part in a later, exploratory step in which the sound is triggered automatically, in real time, based on brain activity patterns.

The sounds used are very quiet, similar in volume to normal conversation, and stimulation is stopped right away if a participant shows any discomfort. The goal of this research is to better understand what triggers Disorders of Arousal, and to test whether sound-based stimulation could one day help study or manage this condition.

Read the full description

Disorders of Arousal (DoA)-including sleepwalking, sleep terrors, and confusional arousals-are NREM parasomnias whose underlying neurophysiological triggers remain poorly understood. A growing body of evidence suggests that DoA episodes do not emerge randomly from sleep but arise from identifiable pre-episode EEG states characterized by increased slow-wave activity and reduced cortical activation, consistent with a transient state of arousal instability. Closed-loop acoustic stimulation (CLAS) is an established, non-invasive method for probing and modulating NREM sleep physiology, but has not previously been applied in the specific context of NREM parasomnias.

This study investigates whether controlled acoustic stimulation, initially delivered with randomized timing and subsequently in a real-time, EEG-triggered closed-loop fashion, can reliably elicit or modulate DoA episodes under supervised laboratory conditions. A small group of healthy volunteers undergoes a single stimulation night to estimate the specificity of stimulation-elicited motor responses, helping distinguish genuine DoA vulnerability from a non-specific arousal response to sound.

The within-subject, randomized-order design in DoA participants allows each to serve as their own control, isolating the effect of acoustic stimulation from other sources of night-to-night variability. The exploratory closed-loop sub-study tests the technical feasibility of triggering stimulation based on real-time EEG markers of vulnerability, representing a first step toward future predictive or modulation-based approaches for this condition.

This study is part of a broader research programme on the neurobiological characterization of Disorders of Arousal; related observational components (including neuroimaging, neuropsychological assessment, and home monitoring) are registered separately.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

For participants with Disorders of Arousal (DoA):

  • Diagnosis of a Disorder of Arousal (sleepwalking, sleep terror, or confusional arousal) per ICSD-3 criteria, confirmed by video-polysomnography or by clinical diagnosis plus a positive Arousal Disorders Questionnaire (ADQ) and compatible history
  • Age 6-17 years (paediatric) or 18-60 years (adult) at enrollment
  • At least one documented episode in the 4 weeks (paediatric) or 6 months (adult) prior to enrollment
  • Ability to understand and complete study materials in Italian
  • Written informed consent (and age-appropriate assent for minors, per Swiss Human Research Act Art. 22-23)

For healthy volunteers:

  • No documented sleep disorder, confirmed by clinical interview, questionnaires, or prior instrumental examination
  • Age- and sex-matched to the paediatric DoA group
  • No clinically significant psychiatric or neurological history
  • Written informed consent and age-appropriate assent

Exclusion Criteria (all participants):

  • Epilepsy or other major neurological disorder
  • Comorbid REM sleep behavior disorder or other REM parasomnia
  • Current psychopharmacological or psychotropic medication (except melatonin ≤2 mg)
  • Neurodevelopmental disorder precluding protocol collaboration (paediatric participants)
  • Clinically relevant sleep-disordered breathing (Apnea-Hypopnea Index \>5 events/hour)
  • Clinically significant hearing deficit
  • Significant sleep deprivation in the 48 hours prior to laboratory recording
  • Pregnancy (adult participants)
  • Inadequate EEG recording quality (\>40% artifact channels or epochs) - applied at the session level
Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment
Random assignment
Masking
Double masked
DoA - No-Stimulation Night (Baseline)

Participants with DoA (N=55) undergo overnight high-density EEG and video-polysomnography with no acoustic stimulation. Within-subject baseline condition; order relative to Arm 2 is randomized per participant.

DoA - Acoustic Stimulation Night

The same DoA participants (N=55) undergo overnight high-density EEG and video-polysomnography with low-intensity open-loop acoustic stimulation delivered during slow-wave sleep; order relative to Arm 1 is randomized per participant. A subset of 10 participants additionally undergoes a later, exploratory real-time closed-loop stimulation sub-phase.

Device: Closed-Loop/Open-Loop Acoustic Stimulation (CLAS)

Healthy Control - Single Stimulation Night

A separate group of healthy participants (N=5) undergoes a single overnight high-density EEG and video-polysomnography recording including open-loop acoustic stimulation during slow-wave sleep, to estimate the specificity of stimulation-elicited motor responses relative to the DoA group.

Device: Closed-Loop/Open-Loop Acoustic Stimulation (CLAS)

Closed-Loop/Open-Loop Acoustic Stimulation (CLAS) DEVICE

Brief, low-intensity auditory stimuli (pure tones or noise bursts, 50-70 dB SPL, approximately 1 second in duration) delivered via a standard speaker during confirmed slow-wave sleep (SWS). In the initial open-loop phase, stimuli are presented with randomized timing. In a later closed-loop sub-study, stimuli are triggered automatically in real time based on predefined EEG features, within randomized vulnerability versus refractory stimulation windows. Stimulation is immediately interrupted in the event of distress, full awakening, or any adverse reaction.

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Number of DoA Episodes During the Stimulation Night Compared With the No-Stimulation Night

Time frame: Assessed during the two laboratory overnight recordings (no-stimulation night and stimulation night), at least 48 hours apart, up to 6 weeks

Number of video-polysomnographically confirmed Disorders of Arousal (DoA) episodes (sleepwalking, sleep terror, or confusional arousal), compared within-subject between the stimulation night and the no-stimulation (baseline) night.

Secondary measures

Duration of DoA Episodes (Seconds): Stimulation Night vs. No-Stimulation Night

Time frame: Assessed during the two laboratory overnight recordings (no-stimulation night and stimulation night), at least 48 hours apart, up to 6 weeks.

Mean duration (seconds) of video-polysomnographically confirmed DoA episodes, compared within-subject between the stimulation night and the no-stimulation (baseline) night.

Proportion of Slow-Wave Sleep Epochs With Successful Stimulation Trigger (Percentage)

Time frame: Assessed during the stimulation-night overnight recording, up to 6 weeks.

Percentage of detected slow-wave sleep epochs in which acoustic stimulation was successfully triggered within the predefined target window, during the stimulation night.

Visual Analogue Scale (VAS) Rating of Perceived Discomfort Related to Acoustic Stimulation

Time frame: Assessed the morning following the stimulation night, up to 6 weeks.

Participant-rated discomfort attributable to acoustic stimulation, using a 0-10 visual analogue scale (0 = no discomfort, 10 = worst imaginable discomfort)

Arousal Index (EEG Arousals per Hour of Sleep): Stimulation Night vs. No-Stimulation Night

Time frame: Assessed during both laboratory overnight recordings (no-stimulation night and stimulation night), up to 6 weeks.

Arousal index (number of EEG-defined arousals per hour of total sleep time, scored per AASM criteria), compared between the stimulation night and the no-stimulation night.

Sleep Efficiency (Percentage): Stimulation Night vs. No-Stimulation Night

Time frame: Assessed during both laboratory overnight recordings (no-stimulation night and stimulation night), up to 6 weeks.

Sleep efficiency (percentage of time in bed spent asleep), derived from polysomnographic sleep staging, compared between the stimulation night and the no-stimulation night.

Other measures

Proportion of DoA Episodes With Reported Conscious Experience: Spontaneous vs. Stimulation-Elicited Episodes

Time frame: Assessed immediately after each DoA episode during both laboratory overnight recordings (no-stimulation night and stimulation night), up to 6 weeks.

Percentage of DoA episodes associated with a reported conscious experience (recalled or unrecalled mental content, assessed via immediate post-episode interview), compared between spontaneous episodes (no-stimulation night) and stimulation-elicited episodes (stimulation night).

Source-Level EEG Spectral Power (Delta 0.5-4 Hz and Beta 18-30 Hz Bands): Spontaneous vs. Stimulation-Elicited DoA Episodes

Time frame: Derived from continuous high-density EEG recorded during both laboratory overnight recordings (no-stimulation night and stimulation night), up to 6 weeks.

Power spectral density in the delta and beta bands, source-localized, compared between spontaneous DoA episodes (no-stimulation night) and stimulation-elicited DoA episodes (stimulation night).

Odds Ratio of DoA Episode Occurrence During EEG-Defined Fragility vs. Refractory Stimulation Windows (Closed-Loop Feasibility)

Time frame: Assessed during the closed-loop pilot phase (Phase 3b), within a subset of participants, up to 6 weeks.

Odds ratio of DoA episode occurrence when stimulation is delivered during EEG-defined fragility windows versus randomly selected refractory windows, in the exploratory closed-loop pilot sub-study.

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Ospedale Italiano di LuganoLugano, Canton Ticino, SwitzerlandStatus unknown

Study team and timeline

Lead sponsor
Anna Castelnovo
Study start
Feb 1, 2027 Estimated
Primary completion
Jul 30, 2030 Estimated
Study completion
Jul 30, 2030 Estimated
First posted
Aug 10, 2026 Actual
Last updated
Nov 10, 2026 Actual

Official study contacts

Anna Castelnovo, MD, PhDCONTACTanna.castelnovo@eoc.ch0041 918116117
Mauro Manconi, MD, PhDCONTACTmauro.manconi@eoc.ch0041918116869
Official study title

Closed-Loop and Open-Loop Acoustic Stimulation During Sleep to Investigate and Modulate Disorders of Arousal in Children and Adults

A HUMAN NEXT STEP

Ask Wellness Clinical Research

Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.

Please do not include medical records, diagnoses, medications, insurance numbers or other sensitive details. This form is for general questions, not urgent care.

Sending a question does not enroll you in a trial.

Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.

Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026